Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer

Alessia Levaggi, Andrea De Maria, Beatrice Dozin, Giuseppina Iacono, Claudia Bighin, Sara Giraudi, Matteo Lambertini, Alessia D'Alonzo, Francesca Poggio, Paolo Pronzato, Lucia Del Mastro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim/Background: Few data are available about the prevalence of hepatitis B and C infections in early breast cancer patients and its impact on systemic treatments. The objectives of this study were to determine the incidence of positive serology for hepatitis B and C in women with early breast cancer and to assess the clinical course and its impact on liver function during adjuvant treatments. Patients and Methods: we retrospectively reviewed hepatitis B and C serology [HBs antigen (HBsAg), HBc antibodies (HBcAb), HBs antibodies (HBsAb) and HC (HCV) antibodies] in 746 consecutive patients with early breast cancer treated at our Institution between 2009 and 2011. Results: Among 375 evaluable patients, we identified 312 controls (83.2%) and 63 patients (16.8%) with positive serology (cases): 15 patients (4%) with HCV, 8 (2.1%) with resolved HBV without anti-HBs (HBsAg-negative, HBsAgAb-negative, HBcAgAb-positive), 36 (9.6%) with resolved HBV with anti-HBs (HBsAg-negative, HBsAgAb-positive, HBcAgAb-positive) and 4 (1%) with chronic HBV (HBsAg-positive, HBsAgAb-negative, HBcAgAb-positive). During systemic treatments, hepatitis (defined as at least a three-fold increase in serum alanine aminotransferase level) occurred in nine (20.4%) out of 44 evaluable cases and in 14 (5.9%) out of 234 evaluable controls. Conclusion: Approximately 20% of patients with early breast cancer with positive serology for viral hepatitis may develop hepatitis during systemic treatment. Pre-treatment serum detection of viral hepatitis B and C antigens and antibodies may be useful in the adjuvant therapy decision-making process and for adequate monitoring of liver function during antineoplastic therapy.

Original languageEnglish
Pages (from-to)3715-3720
Number of pages6
JournalAnticancer Research
Volume34
Issue number7
Publication statusPublished - Jul 1 2014

Fingerprint

Hepatitis C
Hepatitis B
Hepatitis
Breast Neoplasms
Drug Therapy
Serology
Incidence
Hepatitis C Antibodies
Therapeutics
Hepatitis C Antigens
Hepatitis B Antigens
Hepatitis B Antibodies
Antigens
Antibodies
Liver
Serum
Alanine Transaminase
Antineoplastic Agents
Decision Making
Infection

Keywords

  • Breast cancer
  • Chemotherapy
  • Hepatitis B virus
  • Hepatitis C virus

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer. / Levaggi, Alessia; De Maria, Andrea; Dozin, Beatrice; Iacono, Giuseppina; Bighin, Claudia; Giraudi, Sara; Lambertini, Matteo; D'Alonzo, Alessia; Poggio, Francesca; Pronzato, Paolo; Del Mastro, Lucia.

In: Anticancer Research, Vol. 34, No. 7, 01.07.2014, p. 3715-3720.

Research output: Contribution to journalArticle

Levaggi, Alessia ; De Maria, Andrea ; Dozin, Beatrice ; Iacono, Giuseppina ; Bighin, Claudia ; Giraudi, Sara ; Lambertini, Matteo ; D'Alonzo, Alessia ; Poggio, Francesca ; Pronzato, Paolo ; Del Mastro, Lucia. / Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer. In: Anticancer Research. 2014 ; Vol. 34, No. 7. pp. 3715-3720.
@article{81f5e6482b8e42b488d8ff9a30694a5e,
title = "Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer",
abstract = "Aim/Background: Few data are available about the prevalence of hepatitis B and C infections in early breast cancer patients and its impact on systemic treatments. The objectives of this study were to determine the incidence of positive serology for hepatitis B and C in women with early breast cancer and to assess the clinical course and its impact on liver function during adjuvant treatments. Patients and Methods: we retrospectively reviewed hepatitis B and C serology [HBs antigen (HBsAg), HBc antibodies (HBcAb), HBs antibodies (HBsAb) and HC (HCV) antibodies] in 746 consecutive patients with early breast cancer treated at our Institution between 2009 and 2011. Results: Among 375 evaluable patients, we identified 312 controls (83.2{\%}) and 63 patients (16.8{\%}) with positive serology (cases): 15 patients (4{\%}) with HCV, 8 (2.1{\%}) with resolved HBV without anti-HBs (HBsAg-negative, HBsAgAb-negative, HBcAgAb-positive), 36 (9.6{\%}) with resolved HBV with anti-HBs (HBsAg-negative, HBsAgAb-positive, HBcAgAb-positive) and 4 (1{\%}) with chronic HBV (HBsAg-positive, HBsAgAb-negative, HBcAgAb-positive). During systemic treatments, hepatitis (defined as at least a three-fold increase in serum alanine aminotransferase level) occurred in nine (20.4{\%}) out of 44 evaluable cases and in 14 (5.9{\%}) out of 234 evaluable controls. Conclusion: Approximately 20{\%} of patients with early breast cancer with positive serology for viral hepatitis may develop hepatitis during systemic treatment. Pre-treatment serum detection of viral hepatitis B and C antigens and antibodies may be useful in the adjuvant therapy decision-making process and for adequate monitoring of liver function during antineoplastic therapy.",
keywords = "Breast cancer, Chemotherapy, Hepatitis B virus, Hepatitis C virus",
author = "Alessia Levaggi and {De Maria}, Andrea and Beatrice Dozin and Giuseppina Iacono and Claudia Bighin and Sara Giraudi and Matteo Lambertini and Alessia D'Alonzo and Francesca Poggio and Paolo Pronzato and {Del Mastro}, Lucia",
year = "2014",
month = "7",
day = "1",
language = "English",
volume = "34",
pages = "3715--3720",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Incidence of hepatitis in patients with evidence of past or current hepatitis B or C during chemotherapy for early breast cancer

AU - Levaggi, Alessia

AU - De Maria, Andrea

AU - Dozin, Beatrice

AU - Iacono, Giuseppina

AU - Bighin, Claudia

AU - Giraudi, Sara

AU - Lambertini, Matteo

AU - D'Alonzo, Alessia

AU - Poggio, Francesca

AU - Pronzato, Paolo

AU - Del Mastro, Lucia

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Aim/Background: Few data are available about the prevalence of hepatitis B and C infections in early breast cancer patients and its impact on systemic treatments. The objectives of this study were to determine the incidence of positive serology for hepatitis B and C in women with early breast cancer and to assess the clinical course and its impact on liver function during adjuvant treatments. Patients and Methods: we retrospectively reviewed hepatitis B and C serology [HBs antigen (HBsAg), HBc antibodies (HBcAb), HBs antibodies (HBsAb) and HC (HCV) antibodies] in 746 consecutive patients with early breast cancer treated at our Institution between 2009 and 2011. Results: Among 375 evaluable patients, we identified 312 controls (83.2%) and 63 patients (16.8%) with positive serology (cases): 15 patients (4%) with HCV, 8 (2.1%) with resolved HBV without anti-HBs (HBsAg-negative, HBsAgAb-negative, HBcAgAb-positive), 36 (9.6%) with resolved HBV with anti-HBs (HBsAg-negative, HBsAgAb-positive, HBcAgAb-positive) and 4 (1%) with chronic HBV (HBsAg-positive, HBsAgAb-negative, HBcAgAb-positive). During systemic treatments, hepatitis (defined as at least a three-fold increase in serum alanine aminotransferase level) occurred in nine (20.4%) out of 44 evaluable cases and in 14 (5.9%) out of 234 evaluable controls. Conclusion: Approximately 20% of patients with early breast cancer with positive serology for viral hepatitis may develop hepatitis during systemic treatment. Pre-treatment serum detection of viral hepatitis B and C antigens and antibodies may be useful in the adjuvant therapy decision-making process and for adequate monitoring of liver function during antineoplastic therapy.

AB - Aim/Background: Few data are available about the prevalence of hepatitis B and C infections in early breast cancer patients and its impact on systemic treatments. The objectives of this study were to determine the incidence of positive serology for hepatitis B and C in women with early breast cancer and to assess the clinical course and its impact on liver function during adjuvant treatments. Patients and Methods: we retrospectively reviewed hepatitis B and C serology [HBs antigen (HBsAg), HBc antibodies (HBcAb), HBs antibodies (HBsAb) and HC (HCV) antibodies] in 746 consecutive patients with early breast cancer treated at our Institution between 2009 and 2011. Results: Among 375 evaluable patients, we identified 312 controls (83.2%) and 63 patients (16.8%) with positive serology (cases): 15 patients (4%) with HCV, 8 (2.1%) with resolved HBV without anti-HBs (HBsAg-negative, HBsAgAb-negative, HBcAgAb-positive), 36 (9.6%) with resolved HBV with anti-HBs (HBsAg-negative, HBsAgAb-positive, HBcAgAb-positive) and 4 (1%) with chronic HBV (HBsAg-positive, HBsAgAb-negative, HBcAgAb-positive). During systemic treatments, hepatitis (defined as at least a three-fold increase in serum alanine aminotransferase level) occurred in nine (20.4%) out of 44 evaluable cases and in 14 (5.9%) out of 234 evaluable controls. Conclusion: Approximately 20% of patients with early breast cancer with positive serology for viral hepatitis may develop hepatitis during systemic treatment. Pre-treatment serum detection of viral hepatitis B and C antigens and antibodies may be useful in the adjuvant therapy decision-making process and for adequate monitoring of liver function during antineoplastic therapy.

KW - Breast cancer

KW - Chemotherapy

KW - Hepatitis B virus

KW - Hepatitis C virus

UR - http://www.scopus.com/inward/record.url?scp=84906326618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906326618&partnerID=8YFLogxK

M3 - Article

C2 - 24982392

AN - SCOPUS:84906326618

VL - 34

SP - 3715

EP - 3720

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -